» Articles » PMID: 18684712

Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic bone formation in muscle tissue. Recently, a mutation involving a single amino acid substitution in a bone morphogenetic protein (BMP) type I receptor, ALK2, was identified in patients with FOP. We report here that the identical mutation, R206H, was observed in 19 Japanese patients with sporadic FOP. This mutant receptor, ALK2(R206H), activates BMP signaling without ligand binding. Moreover, expression of Smad1 and Smad5 was up-regulated in response to muscular injury. ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin. Taken together, these findings suggest that the heterotopic bone formation in FOP may be induced by a constitutively activated BMP receptor signaling through Smad1 or Smad5. Gene transfer of Smad7 or inhibition of type I receptors with dorsomorphin may represent strategies for blocking the activity induced by ALK2(R206H) in FOP.

Citing Articles

HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity.

Navid F, Chen L, Bowness P, Colbert R Nat Rev Rheumatol. 2024; 21(2):77-87.

PMID: 39623156 DOI: 10.1038/s41584-024-01189-3.


Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe.

Towler O, Shore E, Kaplan F Biomolecules. 2024; 14(8).

PMID: 39199396 PMC: 11353020. DOI: 10.3390/biom14081009.


Fibrodysplasia ossificans progressiva: Two case reports.

Yaynishet Y, Salah F, Gebregiorgis B, Mume A, Damtew H, Amare T Radiol Case Rep. 2024; 19(8):2973-2977.

PMID: 38737178 PMC: 11087907. DOI: 10.1016/j.radcr.2024.04.019.


Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.

Mejias Rivera L, Shore E, Mourkioti F Biomedicines. 2024; 12(4).

PMID: 38672135 PMC: 11048698. DOI: 10.3390/biomedicines12040779.


BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.

Shen H, Gao Y, Ge D, Tan M, Yin Q, Wei T Circulation. 2024; 150(2):132-150.

PMID: 38557054 PMC: 11230848. DOI: 10.1161/CIRCULATIONAHA.123.066430.


References
1.
Kaplan F, Tabas J, Gannon F, Finkel G, Hahn G, Zasloff M . The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. J Bone Joint Surg Am. 1993; 75(2):220-30. DOI: 10.2106/00004623-199302000-00009. View

2.
Lanchoney T, Cohen R, Rocke D, Zasloff M, Kaplan F . Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr. 1995; 126(5 Pt 1):762-4. DOI: 10.1016/s0022-3476(95)70408-6. View

3.
Davies M, Lund R, Mathew S, Hruska K . Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol. 2005; 16(4):917-28. DOI: 10.1681/ASN.2004100835. View

4.
Gannon F, Kaplan F, Olmsted E, FINKEL G, Zasloff M, Shore E . Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum Pathol. 1997; 28(3):339-43. DOI: 10.1016/s0046-8177(97)90133-7. View

5.
Kaplan F, Fiori J, DE LA Pena L, Ahn J, Billings P, Shore E . Dysregulation of the BMP-4 signaling pathway in fibrodysplasia ossificans progressiva. Ann N Y Acad Sci. 2006; 1068:54-65. DOI: 10.1196/annals.1346.008. View